Recent Advances in Type 1 Diabetes Treatment
Understanding Type 1 Diabetes
Type 1 diabetes, also known as juvenile diabetes, is an autoimmune condition where the immune system mistakenly attacks the body’s own pancreatic beta cells. This leads to a deficiency in insulin production, necessitating various treatment strategies focused on managing blood sugar levels. Effective management involves a delicate balance: administering too much insulin can cause hypoglycemia, while too little can result in hyperglycemia. Severe hypoglycemia can lead to seizures and loss of consciousness. Effective diabetes management hinges on two primary components: monitoring blood glucose levels and administering the appropriate amount of insulin.
Glucose Monitoring Techniques
Self-Monitoring of Blood Glucose
Individuals with type 1 diabetes often use portable blood glucose meters for self-monitoring. These devices have evolved, becoming smaller and more precise, requiring only 2–10 μL of blood and providing results within 5-15 seconds. Patients may need to test their glucose levels several times a day, sometimes up to 10 times, especially before and after meals, before exercising, and prior to driving. Some modern monitors can sync with smartphone applications and insulin pumps, allowing for easy data storage and tracking of glucose fluctuations.
Continuous Glucose Monitoring
In recent years, continuous glucose monitors (CGMs) have gained popularity for providing comprehensive data on glucose levels. These devices feature subcutaneous sensors that measure glucose in interstitial fluid every 1-5 minutes. While the readings from CGMs closely align with blood glucose levels under stable conditions, they can experience a delay of 7-8 minutes during rapid glucose changes. Three CGMs have received FDA approval as replacements for traditional glucose meters: the Dexcom G5 (Dexcom, San Diego, CA, USA), Abbott Freestyle Libre (Abbott Diabetes Care, Alameda, CA, USA), and Senseonics Eversense (Senseonics, Germantown, MD, USA).
Insulin Delivery Methods
Direct Injection
Insulin can be administered through direct injection, a method that has seen significant technological advancements. Many patients now utilize insulin pens, which combine a vial and syringe into a single device with disposable or refillable cartridges. Some smart pens can track insulin dosage and timing, relaying this information to smartphones or cloud services for better monitoring. Injections are typically administered once or twice daily, often before meals.
Insulin Pump Therapy
Another option for insulin delivery is insulin pump therapy, which offers continuous subcutaneous insulin administration. This system consists of a small pump connected to a cannula via tubing, although some devices have eliminated tubing for direct needle connections. Insulin pumps are programmable, allowing for varying infusion rates, particularly before meals. They are particularly beneficial for children and individuals with needle anxiety, as the needles are replaced every three days. However, insulin pumps generally cost 1.4 times more than daily injections and may encounter issues with infusion sets.
Progressing Towards the Bionic Pancreas
The future of diabetes management is leaning toward automated insulin delivery systems, often referred to as bionic pancreas technology. These systems typically combine an insulin pump, continuous glucose monitoring, and an algorithm to determine insulin delivery timing. The Medtronic 670G, launched in the USA in 2017 and in Europe in 2018, represents the first automated insulin delivery system. However, it requires users to input meal and carbohydrate information to initiate insulin doses. As of now, the Medtronic 670G is the only regulatory-approved partially automated system, with the Diabeloop system expected to be available in Europe soon. Researchers continue to develop fully automated solutions.
Conclusion
Over the past decade, technology for managing type 1 diabetes has significantly advanced, offering a range of options to help regulate blood glucose levels. Despite these improvements, further research is necessary to optimize these technologies for more efficient insulin management.
Author Information
Written by Tarryn Bourhill, MSc, PhD Candidate.
References
Beck, R. W., Bergenstal, R. M., Laffel, L. M. & Pickup, J. C. Advances in technology for management of type 1 diabetes. The Lancet, doi:10.1016/S0140-6736(19)31142-0.
Association, A. D. 7. Diabetes technology: standards of medical care in diabetes—2019. Diabetes Care 42, S71-S80 (2019).
Daneman, D. Type 1 diabetes. The Lancet 367, 847-858 (2006).
Martin, C. T., Criego, A. B., Carlson, A. L. & Bergenstal, R. M. Advanced Technology in the Management of Diabetes: Which Comes First—Continuous Glucose Monitor or Insulin Pump? Current Diabetes Reports 19, 50 (2019).
Ilonen, J., Lempainen, J. & Veijola, R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nature Reviews Endocrinology, 1-16 (2019).
Kowalski, A. Pathway to artificial pancreas systems revisited: moving downstream. Diabetes care 38, 1036-1043 (2015).
Image by Steve Buissinne from Pixabay.